Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy

Schmader, Kenneth E.; Oxman, Michael N.; Levin, Myron J.; Johnson, Gary R.; Zhang, J. H.; Betts, Robert F.; Morrison, Vicki A.; Gelb, Lawrence D.; Guatelli, John; Harbecke, Ruth; Pachucki, Connie; Keay, Susan; Menzies, Barbara E.; Griffin, Marie R.; Kauffman, Carol A.; Marques, Adriana; Toney, John F.; Keller, Paul M.; Li, X.; Chan, Ivan S. F.; Annunziato, Paula W.

doi:10.1093/cid/cis638

Cited by 208 publications

(155 citation statements)

References 11 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…Up to now, protection has been shown to persist for at least 7 y. 27 Assumptions concerning duration of vaccine-induced protection vary from 7.5 y to lifelong. Follow-up of vaccine efficacy has to be maintained to provide more certainty about the duration of protection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of vaccination against herpes zoster

Boer

Wilschut²,

Postma

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…27 Notably, the vaccine is contraindicated for immunocompromised patients, as it comprises a live attenuated virus. 19 Given all this evidence, vaccination against HZ might be an interesting option for introduction into national immunization programs.…”

Section: Wwwlandesbiosciencecom Human Vaccines and Immunotherapeuticsmentioning

confidence: 99%

Cost-effectiveness of vaccination against herpes zoster

Boer

Wilschut²,

Postma

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The level of cellular immunity determines the risk and severity of HZ and PHN. A weak immune response allows the reactivated virus to replicate unchecked, resulting in higher morbidity [58]. The vaccine's clinical efficacy has been confirmed by two large phase III clinical trials involving more than 38,000 [20] and 22,000 [59] subjects, respectively, aged C60 and 50-59 years.…”

Section: Vaccine Prevention Of Herpes Zoster and Phnmentioning

confidence: 95%

Preventing and managing herpes zoster: key actions to foster healthy aging

et al. 2015

View full text Add to dashboard Cite

Population aging is the demographic phenomenon characterizing all countries in the world, and it is challenging the national infrastructures, in particular health systems. However, aging itself is not associated with increased medical spending, but disability and comorbidity that affect older individuals are the actual drivers for health expenditures. Therefore, if people age in better health, medical spending may be significantly reduced. Preventative interventions proved to be effective in reducing/preventing disease and disability and often found to be cost effective, include diet and exercise interventions, medications, routine disease screenings, and immunizations. Vaccination can protect older citizens against life-threatening diseases, such as influenza, pneumococcal infections, tetanus, and against diseases which adversely impact their quality of life, such as herpes zoster (HZ). Including HZ vaccination in its citizens' lifetime immunization calendar can reinforce Europe's commitment toward active, healthy aging. This paper outlines the consensus statement of a group of Italian experts on HZ.

show abstract

“…In additional substudies 159,160 , efficacy for burden of disease persisted for 10 years after vaccination but efficacy for the incidence of zoster persisted only for 8 years 160 . The CDC currently does not recommend booster doses of the zoster vaccine, but it might do in the future.…”

Section: Preventionmentioning

confidence: 99%